Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESSTORE: Stem Cell Therapy for Stroke
NCT03570450Phase 1Recruiting
- Sponsor
- CHU Grenoble Alpes
- Start
- Jun 2018
- Primary completion
- Jul 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of adipose derived mesenchymal stromal cells in ischemic stroke (5 arms), sponsored by CHU Grenoble Alpes. Primary endpoints: Toxicity (Phase Ia) at 7 days and Dose-effect (Phase Ib) at 6 months. Started Jun 2018; status: recruiting.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03570450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03570450.